

Appendix A – Guidelines Evaluated

Year being evaluated	Year evaluation completed (January to March)	Guidelines evaluated	Guideline Publication Date
2014	2015	Breast Cancer	November 2011
		Cervical Cancer	January 2013
		Prostate Cancer	November 2014
2015	2016	Breast Cancer	November 2011
		Cervical Cancer	January 2013
		Prostate Cancer	November 2014
		Obesity in Adults	February 2015
		Obesity in Children	April 2015
2016	2017	Breast Cancer	November 2011
		Cervical Cancer	January 2013
		Prostate Cancer	November 2014
		Cognitive Impairment	January 2015
		Colorectal Cancer	March 2016
		Lung Cancer	April 2016
		Developmental Delay	May 2016
2017	2018	Breast Cancer	November 2011
		Cervical Cancer	January 2013
		Prostate Cancer	November 2014
		Tobacco Smoking in Children and Adolescents	February 2017
		Hepatitis C	April 2017
2018	2019	Breast Cancer	November 2011
		Cervical Cancer	January 2013
		Prostate Cancer	November 2014
		Impaired Vision	May 2018

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. *CMAJ Open* 2023. doi: 10.9778/cmajo.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at [cmajgroup@cmaj.ca](mailto:cmajgroup@cmaj.ca).

		Asymptomatic Bacteriuria in Pregnancy	July 2018
		Breast Cancer Update	December 2018
2019	2020	Cervical Cancer	January 2013
		Prostate Cancer	November 2014
		Breast Cancer Update	
		Asymptomatic Bacteriuria in Pregnancy	July 2018
		Asymptomatic Thyroid Dysfunction	November 2019
2020	2021	Cervical Cancer	January 2013
		Prostate Cancer	November 2014
		Breast Cancer Update	December 2018
		Asymptomatic Thyroid Dysfunction	November 2019
		Esophageal Cancer	July 2020

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. *CMAJ Open* 2023. doi: 10.9778/cmajo.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at [cmajgroup@cmaj.ca](mailto:cmajgroup@cmaj.ca).

## Appendix B: Task Force Annual Evaluation Interview Script

### Introduction to the Task Force (Factors affecting Reach) [~5 -10 min]

- How did you first learn about the Task Force?
  - Probes: Were you exposed to the Task Force in medical school or your residency training? If so, what did they teach?
- How do you typically hear about new or updated guidelines?
  -

### Experiences with Task Force over time (Effectiveness, factors affecting Adoption) [~5 -10 min ]

*(Note to interviewer: For this area of questioning, important to consider survey results – esp. which guidelines they use.)*

- Describe the extent to which you use/follow recommendations from the Task Force?
  - Do you intend to change your practice to follow any recommendations from the Task Force, and if so, how do you intend to change your practice?
- When did you first start following recommendations from the Task Force? [*\*if they do follow TF guidelines*]
- Could you describe how you make decisions on which recommendations to use/follow?
  - Probe: When a new Task Force recommendation comes out, how do you make a decision on whether or not to follow it?
- What influences your decision to change your preventive health care practices, such as screening?
  - Probe: Can you describe any instances where you changed your practice because of Task Force recommendations?
  - Probe: Have you ever started following a Task Force recommendation and then stopped?
    - Probe: What made you decide to stop? OR What could make you decide to stop following a recommendation?

### Guideline decision making (Effectiveness, factors affecting Adoption) [~ 5 – 10 min]

- From your perspective, where is the main decision-making power for guideline uptake? Who are the influencers that drive guidelines becoming practice?
  - Probe: The practitioner, colleagues, the practice, leaders in the profession, the professional organization, the government, the public?
- What makes a guideline trustworthy?
  - Probes: What are your trusted sources for guidelines?
  - Probe: In your opinion, how does Task Force compare to other sources for guidelines?
  - Probe: Is Task Force trustworthy? Why or why not?
- What makes a guideline easier to implement?
  - Probe: What makes it difficult to implement?
- 
- When you have multiple sources of conflicting information on a preventive health care topic, how do you evaluate which information to follow?
  - Probe: *(Note to interviewer: For this probe, important to consider survey responses.)* Think about a topic where the Task Force and provincial guidelines are different. How did you decide which recommendations to follow?

### Engaging patients (Factors affecting Implementation) [~ 5 – 10 min]

- In your work setting(s), how are patients engaged in discussions about preventive health care? (if at all?)
  - Probe: How do you engage patients in discussions specifically about Task Force recommendations?
  - Probe: (Do you use Task Force KT tools?) How do you use Task Force KT tools?
  -
- In your work setting(s), who else do you think could engage patients in discussions about Task Force recommendations?
  - Probe: How do you think that would work? What support would those people need to engage patients successfully?
  - Probe: Are there any other members of your health care team who engage patients in these discussions?

### Accessing Task Force materials (Suggestions for improving Reach and Implementation) [~5 – 10 min]

- How can the Task Force improve your access to the recommendations and tools?
  - What are the current barriers, if any?
  - What are some recommendations the Task Force could consider to make it easier to access these guidelines/tools?

### Final thoughts and thank you

- Do you have anything else you would like to share?

Thank you so much for taking the time to share with us today. We will be processing and mailing your compensation soon. Please know that the payment processing can take a few weeks. If you have any questions about the evaluation, you can contact [name] at [contact info].

Appendix C – Annual Evaluation Survey

**Task Force 2020 Annual Evaluation**

---

Start of Block: Screening Survey

Q1 Thank you for your interest in the Canadian Task Force on Preventive Health Care ("Task Force") annual evaluation!  
Please answer the following questions to determine your eligibility to participate.

---

Q2 What is your profession? (Select all that apply)

- Primary care physician (1)
- Nurse practitioner (2)
- Nurse (3)
- Resident (4)
- Medical student (5)
- Allied health care professional (e.g. physiotherapist, occupational therapist, physician assistant) (6)
- Researcher (7)
- Other, please specify: (8) \_\_\_\_\_

*Skip To: Q6 If What is your profession? (Select all that apply) = Medical student*  
*Skip To: Q6 If What is your profession? (Select all that apply) = Allied health care professional (e.g. physiotherapist, occupational therapist, physician assistant)*  
*Skip To: Q6 If What is your profession? (Select all that apply) = Nurse*

---

Page Break

Q4 I have conflicts of interest relating to Task Force clinical practice guidelines (e.g., owning shares in a company that sells screening tests).

Yes (1)

No (2)

*Skip To: Q6 If I have conflicts of interest relating to Task Force clinical practice guidelines (e.g., owning sh... = Yes*

Page Break

Q3 Are you practicing primary care in Canada?

Yes (1)

No (2)

*Skip To: Q6 If Are you practicing primary care in Canada? = No*

*Skip To: End of Block If Are you practicing primary care in Canada? = Yes*

Page Break

Q6 Thank you for your interest in participating in the Canadian Task Force on Preventive Health Care (Task Force) annual evaluation. Unfortunately you are not eligible to participate in this study. If you would like to receive newsletters and announcements from the Task Force, please [click here](#) to enter your contact information and be added to our listserv.

Page Break

End of Block: Screening Survey

**Start of Block: Letter of Information**

X→

Q9 Do you consent to participate in the Task Force 2020 annual evaluation survey?

- I **consent** to participate in the annual evaluation survey (0)
- I **do not** consent to participate in the annual evaluation survey (1)

*Skip To: End of Survey If Do you consent to participate in the Task Force 2020 annual evaluation survey? = I <strong>do not</strong> consent to participate in the annual evaluation survey*

End of Block: Letter of Information

---

Start of Block: Current preventive health care practices

Q10 Please respond to the following questions based on your **current preventive health care practices**.

Please note that preventive health care practices, which include screening, target those **who are asymptomatic and not identified as high risk**.

---

Q1 How often do you screen for **breast cancer** with mammography in a woman aged 40 to 49 years?

- Screen the patient every year (1)
  - Screen the patient every two years (2)
  - Screen the patient every three years (3)
  - Screen the patient every four years (4)
  - Do not routinely screen the patient (5)
  - Other: (6) \_\_\_\_\_
-

Q178 How often do you screen for **breast cancer** with mammography in a woman aged 50 to 69 years?

- Screen the patient every year (1)
  - Screen the patient every two years (2)
  - Screen the patient every three years (3)
  - Screen the patient every four years (4)
  - Do not routinely screen the patient (5)
  - Other: (6) \_\_\_\_\_
- 

Q2 How often do you screen a woman for **breast cancer** by conducting a clinical breast exam?

- Screen the patient every year (1)
  - Screen the patient every two years (2)
  - Screen the patient every three years (3)
  - Screen the patient every four years (4)
  - Do not routinely screen the patient (5)
  - Other: (6) \_\_\_\_\_
-



Q3 With which age groups of women do you routinely discuss the harms and benefits of **breast cancer screening**? Select all that apply.

39 and younger (1)

40 to 49 (2)

50 to 69 (3)

70 to 74 (4)

75 and older (5)

I do not routinely discuss the harms and benefits of screening for breast cancer with patients (6)

---

Page Break

Q4 How often do you screen for **cervical cancer** in a woman aged 30 to 69 years?

- Screen the patient every year (1)
  - Screen the patient every two years (2)
  - Screen the patient every three years (3)
  - Screen the patient every four years (4)
  - Do not routinely screen the patient (5)
  - Other: (6) \_\_\_\_\_
- 

Q177 How often do you screen for **cervical cancer** in a woman aged 25 to 29 years?

- Screen the patient every year (1)
  - Screen the patient every two years (2)
  - Screen the patient every three years (3)
  - Screen the patient every four years (4)
  - Do not routinely screen the patient (5)
  - Other: (6) \_\_\_\_\_
-

Q5 How often do you screen for **cervical cancer** in a woman younger than 25 years old?

- Screen the patient every year (1)
  - Screen the patient every two years (2)
  - Screen the patient every three years (3)
  - Screen the patient every four years (4)
  - Do not routinely screen the patient (5)
  - Other: (6) \_\_\_\_\_
- 

Q6 With which age groups of women do you routinely discuss the harms and benefits of **cervical cancer screening**? Select all that apply.

- 19 and younger (1)
  - 20 to 24 (2)
  - 25 to 29 (3)
  - 30 to 69 (4)
  - 70 and older (5)
  - I do not routinely discuss the harms and benefits of screening for cervical cancer with patients (6)
- 

Page Break

Q7 With which age groups of men do you routinely discuss the harms and benefits of **prostate cancer screening**? Select all that apply.

54 and younger (1)

55 to 69 (2)

70 and older (3)

I do not routinely discuss the harms and benefits of screening for prostate cancer with patients (4)

---

Q9 How often do you screen for **prostate cancer** with the PSA test in a man younger than 55 years old?

Screen the patient every year (1)

Screen the patient every two years (2)

Screen the patient every three years (3)

Screen the patient every four years (4)

Do not routinely screen the patient (5)

Other: (6) \_\_\_\_\_

---

Q8 How often do you screen for **prostate cancer** with the PSA test in a man 55 to 69 years old?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: (6) \_\_\_\_\_

---

Page Break

Q10 How often do you screen for **esophageal adenocarcinoma** in patients with chronic gastroesophageal reflux disease ?

- Screen the patient every year (1)
  - Screen the patient every two years (7)
  - Screen the patient every three years (8)
  - Screen the patients every four years (10)
  - Do not routinely screen the patient (11)
  - Other: (6) \_\_\_\_\_
- 

Q11 With which age groups of patients with chronic gastroesophageal reflux disease do you routinely discuss the harms and benefits of screening for for **esophageal adenocarcinoma**?

- 18 and older (1)
  - 17 and younger (5)
  - I do not routinely discuss the harms and benefits of screening for asymptomatic bacteriuria with pregnant patients (4)
- 

Page Break

Q12 How often do you screen for **thyroid dysfunction** in asymptomatic non-pregnant adults?

- Screen the patient every year (1)
  - Screen the patient every two years (7)
  - Screen the patient every three years (8)
  - Screen the patient every four years (9)
  - Do not routinely screen the patient (2)
  - Other: (6) \_\_\_\_\_
- 

Q13 With which age groups of asymptomatic non-pregnant patients do you routinely discuss the harms and benefits of screening for **thyroid dysfunction**?  
Please select all that apply

- 17 and younger (1)
  - 18 - 30 (4)
  - 31 - 60 (6)
  - 61 and older (7)
  - I do not routinely discuss the harms and benefits of screening for thyroid dysfunction with non-pregnant asymptomatic patients (5)
- 

Page Break

Q14 The CTFPHC grades recommendations as either “strong” or “conditional” according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

The Task Force previously used the term “**weak recommendation**”, but has replaced this with the term “**conditional recommendation**”, to improve understanding and facilitate implementation of guidance, based on feedback from clinician knowledge users.

“Conditional recommendations” result when the balance between desirable and undesirable effects is small, the quality of evidence is lower, and there is more variability in the values and preferences of individuals.

---

Q15 Are you aware of the recent change of language from “weak” to “conditional”?

- Yes (1)
  - No (4)
- 

Q16 In your experience, does the language change from “weak” to “conditional” help facilitate the implementation of recommendations where the balance between desirable and undesirable effects is small, the quality of evidence is lower, and there is more variability in the values and preferences of individuals?

- Yes (1)
  - No (4)
  - Not sure (5)
- 

Q17 (Optional) Please describe any additional thoughts you have on how the wording used to describe ‘conditional’ or ‘weak’ recommendations may impact implementation.

---

---

---

---

---



End of Block: Current preventive health care practices

---

Start of Block: Use and satisfaction with guidelines

Q18 For the following preventive health topics, please indicate whether you primarily use provincial/territorial or national clinical practice guidelines.

---

Q19 Breast cancer screening

- Task Force national guideline (1)
  - Other national guideline: (2) \_\_\_\_\_
  - Provincial/territorial (3)
  - Other guideline: (4) \_\_\_\_\_
  - I do not follow a guideline (5)
- 

Q20 Cervical cancer screening

- Task Force national guideline (1)
  - Other national guideline: (2) \_\_\_\_\_
  - Provincial/territorial (3)
  - Other guideline: (4) \_\_\_\_\_
  - I do not follow a guideline (5)
-

Q21 Prostate cancer screening

- Task Force national guideline (1)
  - Other national guideline: (2) \_\_\_\_\_
  - Provincial/territorial (3)
  - Other guideline: (4) \_\_\_\_\_
  - I do not follow a guideline (5)
- 

Q22 Esophageal adenocarcinoma with chronic gastroesophageal reflux disease screening

- Task Force national guideline (1)
  - Other national guideline: (2) \_\_\_\_\_
  - Provincial/territorial (3)
  - Other guideline: (4) \_\_\_\_\_
  - I do not follow a guideline (5)
-

Q23 Thyroid dysfunction screening

- Task Force national guideline (1)
- Other national guideline: (2) \_\_\_\_\_
- Provincial/territorial (3)
- Other guideline: (4) \_\_\_\_\_
- I do not follow a guideline (5)

---

Page Break

Q24 We will now ask you some questions about the Canadian Task Force for Preventive Health Care (Task Force) guidelines, tools, and resources.

---

Q25 Which Task Force clinical practice guidelines are you **aware** of? Select all that apply.

- Breast cancer screening update (released December 2018) (9)
- Cervical cancer screening (2)
- Prostate cancer screening (10)
- Esophageal cancer screening (3)
- Thyroid dysfunction screening (6)
- I am not aware of any of the above Task Force screening guidelines (8)

*Skip To: End of Block If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = I am not aware of any of the above Task Force screening guidelines*

Page Break

---

Carry Forward Selected Choices from "Which Task Force clinical practice guidelines are you aware of? Select all that

Q26 How **satisfied** are you with the following Task Force guideline recommendations?

1 – Not at all satisfied

4 – Neither satisfied nor dissatisfied

7 – Very satisfied.

	1 (1)	2 (2)	3 (3)	4 (4)	5 (5)	6 (6)	7 (7)
Breast cancer screening update (released December 2018) (x9)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Cervical cancer screening (x2)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Prostate cancer screening (x10)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Esophageal cancer screening (x3)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Thyroid dysfunction screening (x6)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<input checked="" type="checkbox"/> I am not aware of any of the above Task Force screening guidelines (x8)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

---

Q27 Please provide any explanation or comments for your dissatisfaction with Task Force guideline recommendations.

---

---

---

---

---

---

Page Break

*Display This Question:*

*If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Breast cancer screening update (released December 2018)*

Q28 Have you changed your practice to align with the Task Force breast cancer guideline update since its release in 2018?

- Yes, I have made changes in my practice to specifically align with the Task Force breast cancer screening guideline (1)
- No, I have not made changes in my practice to specifically align with the Task Force breast cancer screening guideline (2)
- My practice was already consistent with the guideline (e.g. I began practicing after the guideline was released and I've always followed the Task Force recommendation, or my practice was already consistent with the Task Force recommendations when this guideline was released) (3)

---

*Display This Question:*

*If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Cervical cancer screening*



Q29 Have you changed your practice to align with the Task Force cervical cancer screening guideline since its release in 2013?

- Yes, I have changed my practice to align with the updated Task Force cervical cancer screening guideline (1)
- No, I have not changed my practice to align with the updated Task Force cervical cancer screening guideline (5)
- My practice was already consistent with the guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I've always followed the Task Force recommendation) (6)

---

*Display This Question:*

*If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Prostate cancer screening*

Q30 Have you changed your practice to align with the Task Force prostate cancer screening guideline since its release in 2014?

- Yes, I have changed my practice to align with the Task Force prostate cancer screening guideline (1)
- No, I have not changed my practice to align with the Task Force prostate cancer screening guideline (5)
- My practice was already consistent with the Task Force prostate cancer guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I've always followed the Task Force recommendations (6)

---

*Display This Question:*

*If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Esophageal cancer screening*

Q31 Have you changed your practice to align with the Task Force esophageal adenocarcinoma screening guideline since its release in 2020?

- Yes, I have made changes in my practice to specifically align with the Task Force esophageal adenocarcinoma screening guideline (1)
- No, I have not made changes in my practice to specifically align with the Task Force esophageal adenocarcinoma screening guideline (2)
- My practice was already consistent with the Task Force esophageal adenocarcinoma screening guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I've always followed the Task Force recommendation) (3)

*Display This Question:*

*If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Thyroid dysfunction screening*

Q32 Have you changed your practice to align with the Task Force thyroid dysfunction screening guideline since its release in 2019?

- Yes, I have made changes in my practice to specifically align with the Task Force thyroid screening guideline (1)
- No, I have not made changes in my practice to specifically align with the Task Force thyroid screening guideline (2)
- My practice was already consistent with the thyroid screening guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I've always followed the Task Force recommendation) (3)

*Display This Question:*

*If Which Task Force clinical practice guidelines are you aware of? Select all that apply. != I am not aware of any of the above Task Force screening guidelines*

*And Have you changed your practice to align with the Task Force breast cancer guideline update since... = No, I have not made changes in my practice to specifically align with the Task Force breast cancer screening guideline*

*Or Have you changed your practice to align with the Task Force cervical cancer screening guideline s... = No, I have not changed my practice to align with the updated Task Force cervical cancer screening guideline*

*Or Have you changed your practice to align with the Task Force prostate cancer screening guideline s... = No, I have not changed my practice to align with the Task Force prostate cancer screening guideline*

*Or Have you changed your practice to align with the Task Force esophageal adenocarcinoma screening g... = No, I have not made changes in my practice to specifically align with the Task Force esophageal adenocarcinoma screening guideline*

*Or Have you changed your practice to align with the Task Force thyroid dysfunction screening guideli... = No, I have not made changes in my practice to specifically align with the Task Force thyroid screening guideline*

Q33 The following table lists the Task Force screening guidelines for which you indicated you have **not** made changes in your practice to specifically align with the Task Force recommendations. Do you **intend** to make practice changes to align with any of the following Task Force guidelines?

	I <b>intend</b> to align my practice with this Task Force guideline (1)	I <b>do not intend</b> to align my practice with this Task Force guideline (2)	I haven't decided yet (3)
<p><i>Have you changed your practice to align with the Task Force prostate cancer screening guideline s... = No, I have not changed my practice to align with the Task Force prostate cancer screening guideline</i></p> <p><b>Esophageal adenocarcinoma (1)</b></p>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<p><i>Have you changed your practice to align with the Task Force thyroid dysfunction screening guideli... = No, I have not made changes in my practice to specifically align with the Task Force thyroid screening guideline</i></p> <p><b>Thyroid dysfunction (2)</b></p>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
<p><i>Have you changed your practice to align with the Task Force cervical cancer screening guideline s... = No, I have not changed my practice to align with the updated Task Force cervical cancer screening guideline</i></p> <p><b>Cervical cancer (3)</b></p>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

*Have you changed your practice to align with the Task Force esophageal adenocarcinoma screening g... = No, I have not made changes in my practice to specifically align with the Task Force esophageal adenocarcinoma screening guideline*

**Prostate cancer (4)**



*Have you changed your practice to align with the Task Force breast cancer guideline update since... = No, I have not made changes in my practice to specifically align with the Task Force breast cancer screening guideline*

**Breast Cancer (5)**



End of Block: Use and satisfaction with guidelines

---

Start of Block: Tools and resources

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. != I am not aware of any of the above Task Force screening guidelines

Q34 Are you **aware of** or **have you used** any of the following Task Force tools that accompany the clinical practice guidelines? Select all that apply.

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Breast cancer screening update (released December 2018)

Q36 Breast cancer screening update (2018) tools

	I am <b>aware</b> of this tool (1)	I have <b>used</b> this tool (2)
1000-person tool (1)	<input type="checkbox"/>	<input type="checkbox"/>
1000-person tool, age 40-49 (2)	<input type="checkbox"/>	<input type="checkbox"/>
1000-person tool, age 50-59 (3)	<input type="checkbox"/>	<input type="checkbox"/>
1000-person tool, age 60-69 (4)	<input type="checkbox"/>	<input type="checkbox"/>
1000-person tool, age 70-74 (5)	<input type="checkbox"/>	<input type="checkbox"/>

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Cervical cancer screening

Q46 Cervical cancer screening tools

	I am <b>aware</b> of this tool (1)	I have <b>used</b> this tool (2)
Clinician algorithm (1)	<input type="checkbox"/>	<input type="checkbox"/>
Clinician FAQ (2)	<input type="checkbox"/>	<input type="checkbox"/>
Patient algorithm (3)	<input type="checkbox"/>	<input type="checkbox"/>
Patient FAQ (4)	<input type="checkbox"/>	<input type="checkbox"/>

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Prostate cancer screening

Q47 Prostate cancer screening tools

	I am <b>aware</b> of this tool (1)	I have <b>used</b> this tool (2)
Clinician FAQ (1)	<input type="checkbox"/>	<input type="checkbox"/>
Patient FAQ (2)	<input type="checkbox"/>	<input type="checkbox"/>
1000-person tool (3)	<input type="checkbox"/>	<input type="checkbox"/>
Infographic (4)	<input type="checkbox"/>	<input type="checkbox"/>
CTFPHC prostate-specific antigen screening video (5)	<input type="checkbox"/>	<input type="checkbox"/>

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Esophageal cancer screening

Q48 Esophageal adenocarcinoma screening tools

	I am <b>aware</b> of this tool (1)	I have <b>used</b> this tool (2)
Clinician FAQ (1)	<input type="checkbox"/>	<input type="checkbox"/>
Patient FAQ (2)	<input type="checkbox"/>	<input type="checkbox"/>

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Thyroid dysfunction screening

Q49 Thyroid dysfunction screening tool

	I am <b>aware</b> of this tool (1)	I have <b>used</b> this tool (2)
Clinician FAQ (1)	<input type="checkbox"/>	<input type="checkbox"/>

Page Break

Q50 How do you access the Task Force tools? Select all that apply.

Q51 Digital

I view them on the Task Force website (1)

I view them on the Task Force mobile app (*Please note: Task Force mobile app is no longer being updated. Our guidelines and tools are now included in the app QxMD Calculate.*) (2)

I view them on the QxMD mobile app (3)



Q52 Print

I printed copies for myself (1)

I have printed copies that came with my CMAJ publication (*Please note: printed copies of CTFPHC tools are no longer sent with CMAJ publications, as of 2018*) (2)

I received laminated copies at a conference (i.e. FMF, MFC) (3)

---

Q53 Other

---

Page Break

---

Q54 Are you **aware of** or **have you used** any of the following resources? Select all that apply

---

Q55

	Task Force Newsletter (1)	Task Force Twitter account (2)	Task Force website (9)	Lung Cancer Screening video (11)	QxMD Calculate mobile application (3)	Task Force Cervical Cancer Screening e-learning module (4)	Task Force Obesity Prevention and Management e-learning module (5)	Task Force Canadian Family Physician (CFP) article series: 'Prevention in Practice' (6)	Task Force Periodic Health Visits article in Canadian Family Physician (CFP) (7)	Task Force CMAJ Clinical Practice Guideline author podcasts (8)	Prevention+ Website (12)	ECRI Guidelines Trust website (13)
I am aware of this resource (1)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
I have used this resource (e.g. read it, referred to it) (2)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Page Break

Page Break

Q62 Please provide any additional comments or feedback you have on the Task Force guidelines, tools, or resources.

---

---

---

---

---

End of Block: Tools and resources

---

Start of Block: Demographics

Q63 What is your gender?

- Male (1)
- Female (2)
- Non-binary (3)
- Prefer to self-describe (4) \_\_\_\_\_
- Prefer not to say (5)

Q64 In which province or territory do you practice?

- British Columbia (1)
  - Alberta (2)
  - Saskatchewan (3)
  - Manitoba (4)
  - Ontario (5)
  - Quebec (6)
  - New Brunswick (7)
  - Nova Scotia (8)
  - Newfoundland (9)
  - Prince Edward Island (10)
  - Yukon (11)
  - Northwest Territories (12)
  - Nunavut (13)
-

Q65 How old are you?

- 20 to 29 (1)
  - 30 to 39 (2)
  - 40 to 49 (3)
  - 50 to 59 (4)
  - 60 to 69 (5)
  - 70 to 79 (6)
  - 80 or older (7)
- 

Q66 How many years have you been practicing?

- 5 or fewer (1)
- 6 to 10 (2)
- 11 to 15 (3)
- 16 to 20 (4)
- 21 to 25 (5)
- 26 to 30 (6)
- 31 to 35 (7)
- 36 to 40 (8)
- 41 or more (9)

---

Q67 What is your clinical setting? Select all that apply.

Urban (1)

Suburban (2)

Rural (3)

Other, please specify: (4) \_\_\_\_\_

---

Q68 What language do you primarily practice in (select all that apply)?

English (4)

French (5)

Mandarin (6)

Cantonese (7)

Punjabi (8)

Spanish (9)

Other(please specify): (10) \_\_\_\_\_

---

Q69 What is your clinic type? Select all that apply.

- Hospital-based (1)
  - Community-based (2)
  - Multidisciplinary clinic (3)
  - Physician group clinic (4)
  - Single practitioner clinic (5)
  - Other, please specify: (6) \_\_\_\_\_
- 

Q179 How did you hear about this survey?

- Task Force Newsletter (1)
  - Email (2)
  - Twitter (3)
  - Task Force website (5)
  - Friend/colleague (6)
  - Other (please describe); (4) \_\_\_\_\_
- 

Page Break

Q70 Are you willing to participate in a one hour follow-up interview? The interview will ask you about your experiences with the Task Force and about how you use guidelines in your practice.

If you complete an interview, you will receive a \$100 honorarium. If you do not want to participate in the interview, you can enter a draw for an iPad.

- Yes, I will participate in an interview (1)
- No, I am not willing to participate in an interview (2)
- 

Page Break

Q71 Would you like to be entered into the draw to win an iPad? The winner will be drawn randomly in Spring 2021. Your contact information will be kept confidential.

- Yes (1)
- No (2)
- 

Q72 The Canadian Task Force on Preventive Health Care has a mailing list that we use to send occasional emails about our work, including guideline and tool updates. We also send emails to the mailing list to recruit primary care practitioners to review tools and provide input into our research projects. Would you be interested in being added to our mailing list?

- Yes (1)
- No (2)
- 

Page Break



## Appendix D – Coding Framework

RE-AIM Domain	Parent Node	Child Nodes
Reach	<p>What do you hear about CTFPHC</p> <p><i>Explores what the participants has heard about the CTFPHC, the perception of the CTFPHC</i></p>	<ul style="list-style-type: none"> <li>• Neutral</li> <li>• Positive</li> <li>• Negative</li> </ul>
	<p>Initial Intro to CTFPHC</p> <p><i>Explores where the participant was first introduced to the CTFPHC</i></p>	<ul style="list-style-type: none"> <li>• Other</li> <li>• Medical School and Residency <ul style="list-style-type: none"> <li>○ Preceptors</li> <li>○ Colleagues</li> </ul> </li> <li>• Dissemination activities <ul style="list-style-type: none"> <li>○ Newsletter</li> <li>○ KT tools</li> <li>○ Website</li> <li>○ App</li> </ul> </li> <li>• Conferences</li> <li>• Colleagues</li> </ul>
Effectiveness	<p>Source of Guidelines</p> <p><i>The sources from which participants access guidelines</i></p>	<ul style="list-style-type: none"> <li>• Other national organization</li> <li>• CTFPHC</li> <li>• No source (general)</li> <li>• Specialist organizations</li> </ul>
	<p>Trustworthiness</p> <p><i>Explores the factors which participants identify as lending to the credibility of guidelines</i></p>	<ul style="list-style-type: none"> <li>• Composition of guideline developers (diverse experts)</li> <li>• Conflicts of interest/ bias/ funding</li> <li>• Quality of evidence</li> <li>• Specialist input</li> <li>• Popularity among colleagues</li> <li>• Transparency (methods)</li> <li>• Other</li> </ul>
Adoption	<p>Adoption of Guidelines and Tools</p> <p><i>Factors which help participants determine their use of guidelines and tools</i></p>	<ul style="list-style-type: none"> <li>• Relevance to practice</li> <li>• National vs. provincial vs. international</li> <li>• Practitioner</li> <li>• Avenues for guideline information</li> <li>• Clear and concise</li> <li>• Colleagues</li> <li>• Consensus</li> </ul>

		<ul style="list-style-type: none"> <li>• Policies</li> <li>• Physician values/ preferences</li> <li>• Patients</li> <li>• Media</li> <li>• Clinical experience</li> <li>• Feasibility</li> <li>• Evidence</li> </ul>
Implementation	<p>Impacting Factors/ Determinants of Use <i>Explores the barriers and facilitators that impact participants' implementation of guidelines and tools</i></p>	<ul style="list-style-type: none"> <li>• EMR integration <ul style="list-style-type: none"> <li>○ Barrier</li> <li>○ Facilitator</li> </ul> </li> <li>• Resources <ul style="list-style-type: none"> <li>○ Barrier</li> <li>○ Facilitator</li> </ul> </li> <li>• Ease of use <ul style="list-style-type: none"> <li>○ Barrier</li> <li>○ Facilitator</li> </ul> </li> <li>• Colleagues <ul style="list-style-type: none"> <li>○ Barrier</li> <li>○ Facilitator</li> </ul> </li> <li>• Patients <ul style="list-style-type: none"> <li>○ Barrier</li> <li>○ Facilitator</li> </ul> </li> <li>• Other</li> </ul>
	<p>Use of KT Tools <i>Participants who have selected as using or not using KT tools</i></p>	<ul style="list-style-type: none"> <li>• Yes</li> <li>• No</li> </ul>
	<p>Access to KT Tools <i>Different avenues of accessing KT tools</i></p>	<ul style="list-style-type: none"> <li>• Website</li> <li>• Hard copies</li> <li>• App</li> <li>• Google (search engine)</li> </ul>
	<p>Suggestions for Increasing Awareness <i>Participants' recommendations for increasing users' awareness of updated and upcoming guidelines and tools</i></p>	<ul style="list-style-type: none"> <li>• Website</li> <li>• Conferences</li> <li>• Search engine optimization</li> <li>• Emails</li> </ul>
	<p>Alignment of Practice with Guidelines <i>Examples of participants' alignment of practice with existing guidelines</i></p>	<ul style="list-style-type: none"> <li>• Alignment examples</li> <li>• Non-alignment examples</li> </ul>

Maintenance	Recall <i>How participants hear about new/ updated guidelines</i>	<ul style="list-style-type: none"> <li>• Website</li> <li>• Newsletter</li> <li>• Colleagues</li> <li>• Conferences</li> </ul>
	Suggestions for Increasing Awareness <i>Participants' suggestions on strategies to increase practitioners awareness of Task Force guidelines and/or KT tools</i>	<ul style="list-style-type: none"> <li>• Attend conferences</li> <li>• Medical school</li> <li>• Social media</li> <li>• Advertisements</li> </ul>